These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7641591)

  • 41. Potentiation of C1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection.
    Dalmasso AP; Platt JL
    Transplant Proc; 1994 Jun; 26(3):1246-7. PubMed ID: 8029898
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of combined expression of human complement regulatory proteins and H-transferase on the inhibition of complement-mediated cytolysis in porcine embryonic fibroblasts.
    Lee JH; Lee HJ; Nahm KM; Jeon HY; Hwang WS; Paik NW; Rho HM
    Transplant Proc; 2006 Jun; 38(5):1618-21. PubMed ID: 16797369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological manipulation of complement system.
    Asghar SS
    Pharmacol Rev; 1984 Dec; 36(4):223-44. PubMed ID: 6395140
    [No Abstract]   [Full Text] [Related]  

  • 44. The regulation of complement activity by pharmacologic agents.
    Reynard AM
    J Immunopharmacol; 1980; 2(1):1-47. PubMed ID: 6256451
    [No Abstract]   [Full Text] [Related]  

  • 45. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.
    Gasque P; Neal JW; Singhrao SK; McGreal EP; Dean YD; Van BJ; Morgan BP
    Mol Neurobiol; 2002 Feb; 25(1):1-17. PubMed ID: 11890454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immunologic defense mechanism by activation of the complement system and arachidonic acids].
    Takahashi K
    Nihon Rinsho; 1988 Sep; 46(9):1987-92. PubMed ID: 3241390
    [No Abstract]   [Full Text] [Related]  

  • 47. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The complement system as a therapeutic target in autoimmunity.
    Holers VM
    Clin Immunol; 2003 Jun; 107(3):140-51. PubMed ID: 12804527
    [No Abstract]   [Full Text] [Related]  

  • 49. Complestatin, a potent anti-complement substance produced by Streptomyces lavendulae. I. Fermentation, isolation and biological characterization.
    Kaneko I; Kamoshida K; Takahashi S
    J Antibiot (Tokyo); 1989 Feb; 42(2):236-41. PubMed ID: 2925515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Superiority of human complement for assaying bacterial lipopolysaccharides by their anticomplementary activity.
    Saddler JN; Wardlaw AC
    Experientia; 1978 Sep; 34(9):1227-8. PubMed ID: 363447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New approach to prevent complement activation on xenografts: effects of a surface-bound form of human C4b binding protein.
    Mikata S; Miyagawa S; Kamiike W; Ito T; Matsuda H; Iwata K; Nagasawa S; Seya T; Shirakura R
    Transplant Proc; 1998 Feb; 30(1):65-6. PubMed ID: 9474958
    [No Abstract]   [Full Text] [Related]  

  • 52. Complement: the Iceman of immunology?
    Würzner R
    Immunopharmacology; 1997 Dec; 38(1-2):63-4. PubMed ID: 9476115
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological manipulation of the complement system in human diseases.
    Asghar SS
    Front Biosci; 1996 Mar; 1():e15-25. PubMed ID: 9159241
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The future use of complement inhibitors for the treatment of neurological diseases.
    McGeer EG; McGeer PL
    Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complement: Bridging the innate and adaptive immune systems in sterile inflammation.
    Lo MW; Woodruff TM
    J Leukoc Biol; 2020 Jul; 108(1):339-351. PubMed ID: 32182389
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Complement therapeutics; history and current progress.
    Morgan BP; Harris CL
    Mol Immunol; 2003 Sep; 40(2-4):159-70. PubMed ID: 12914822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemical Approaches to Modulating Complement-Mediated Diseases.
    Iyer A; Xu W; Reid RC; Fairlie DP
    J Med Chem; 2018 Apr; 61(8):3253-3276. PubMed ID: 28977749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complement as a mediator of vascular inflammation and activation in allografts.
    Baldwin WM; Qian Z; Ota H; Samaniego M; Wasowska B; Sanfilippo F; Hruban RH
    J Heart Lung Transplant; 2000 Aug; 19(8):723-30. PubMed ID: 10967264
    [No Abstract]   [Full Text] [Related]  

  • 59. Complement in atherosclerosis: friend or foe?
    Speidl WS; Kastl SP; Huber K; Wojta J
    J Thromb Haemost; 2011 Mar; 9(3):428-40. PubMed ID: 21155967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The complement system in host defense and inflammation: the cutting edges of a double edged sword.
    Johnston RB
    Pediatr Infect Dis J; 1993 Nov; 12(11):933-41. PubMed ID: 8265285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.